NCI to Launch Phase 2 Clinical Trial of Exelixis' Cabozantinib and BMS' Nivolumab
Novel Combination Strategy for Treating Refractory Melanoma and Head and Neck Cancer
Despite the growth of the global Immune Checkpoint Inhibitor market, treatment options remain limited for patients who relapse or are unresponsive to existing anti-PD-1 therapies. This Phase 2 clinical trial aims to overcome this limitation by combining Cabometyx (cabozantinib), a multi-target tyrosine kinase inhibitor (TKI) from Exelixis (EXEL), with Opdivo (nivolumab), a PD-1 inhibitor from Bristol Myers Squibb (BMS, BMY). Cabozantinib blocks VEGFR 1/2/3, MET, and AXL, converting the tumor microenvironment into an immune-activated state, while nivolumab reactivates suppressed T cells, creating a synergistic effect. This combination not only offers a new treatment pathway for refractory patients but also has the potential to prevent drug resistance, a key limitation of existing single-agent therapies.
Implementation of Precision Medicine Screening Using Biomarkers
This study goes beyond simple drug combination by employing a personalized medicine strategy that analyzes patient biomarkers to predict response. The clinical trial (NCT05136196, BiCaZO study) pre-screens patients for tumor mutational burden (TMB) and tumor inflammation signature (TIS) gene expression profiles, classifying them into biological clusters and tracking treatment response. This will help determine which molecular genetic characteristics are associated with the best response to targeted and immune combination therapies. This approach will increase patient-specific response rates and reduce unnecessary side effects, demonstrating the clinical feasibility of precision medicine.
Regulatory History and Clinical Positioning of the Developers
Cabometyx has accumulated strong clinical data since its initial FDA approval in 2016 as a treatment for renal cell carcinoma (RCC), with subsequent expansion of indications to hepatocellular carcinoma (HCC) and differentiated thyroid cancer (DTC). Opdivo has also become a standard of care for various solid tumors, including melanoma, generating billions of dollars in annual revenue. This trial is led by the National Cancer Institute (NCI) and, based on the companies' approval history, has the potential to create opportunities for supplemental New Drug Applications (sNDAs) for the combination therapy. Beyond the development of a commercial pipeline, this represents an opportunity to demonstrate the long-term efficacy of the drug and its academic credibility through a public-interest clinical design.
Market Competitive Landscape and Long-Term Commercial Value
The global melanoma treatment market is estimated at $5.8 billion to $7.4 billion in 2024, and the head and neck cancer treatment market is also experiencing high growth, with an estimated size of $2.5 billion to $6.8 billion. Currently, Merck (MRK)'s Keytruda (pembrolizumab) holds a dominant position in this market, making it essential for latecomers to build strong combination pipelines. If this trial demonstrates efficacy in patients with refractory melanoma and head and neck squamous cell carcinoma (HNSCC) who have failed first-line anti-PD-1 therapy, it could capture a niche market and potentially become a leading treatment option in the high unmet need second-line therapy market. This will maximize the oncology franchise value of Exelixis and BMS and contribute significantly to the positioning of subsequent products.
This Phase 2 clinical trial represents a strategic effort by Exelixis (EXEL) and BMS (BMY) to target patients who have failed existing anti-PD-1 therapies in the global melanoma and head and neck cancer markets, which combined are worth approximately $10 billion annually. The multi-target mechanism of Cabometyx (VEGFR/MET/AXL) and the synergy with Nivolumab are considered a promising pipeline to counter the dominance of Merck (MRK)'s Keytruda. In particular, the TMB and TIS biomarker classification approach provides a model for precision medicine that increases the success rate of new drug clinical trials and reduces costs. In the short term, demonstrating efficacy in patients unresponsive to anti-PD-1 therapy will be a key factor in defending the companies' revenues, and in the long term, the expansion of approved indications is expected to lead to market leadership. As the study is led by the National Cancer Institute (NCI), the data will be reliable and highly persuasive in future regulatory approvals and commercialization processes.
Source: ClinicalTrials.gov (api_ct)